enGene is a private biotechnology company based in Vancouver, Canada developing a proprietary genetic technology to induce specific cells in the gut to produce therapeutic proteins in a meal-dependent fashion, thus offering a unique therapeutic solution to treating metabolic diseases such as diabetes and obesity.
enGene's proprietary technologies include a revolutionary therapeutic strategy to treat diabetes by inducingspecific gut cells to produce insulin automatically in a meal-dependent manner. This technology couldprovide a long-term or even permanent treatment for Type 1 diabetes, replacing the need for external administration of insulin. GEMS(tm) (Gut Endocrine-cell Modification System) is now in preclinical development as the basis for an effective treatment for diabetes and other metabolic disorders whereintermittent meal-regulated delivery of therapeutic proteins is desirable
| enGene Inc. Completes US$6.4M Series A Financing | 03/18/2008 - 07:00 | $6Million |